• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Journal of Advanced Pharmacy Research
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 9 (2025)
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 8 (2024)
Volume Volume 7 (2023)
Volume Volume 6 (2022)
Volume Volume 5 (2021)
Volume Volume 4 (2020)
Volume Volume 3 (2019)
Volume Volume 2 (2018)
Volume Volume 1 (2017)
Abdul Bari, M. (2025). The Therapeutic Effects of Sulfasalazine Ointment on Imiquimod-Induced Psoriasis in Mice. Journal of Advanced Pharmacy Research, 9(3), 120-128. doi: 10.21608/aprh.2025.378030.1313
Mohammed Abdul Bari. "The Therapeutic Effects of Sulfasalazine Ointment on Imiquimod-Induced Psoriasis in Mice". Journal of Advanced Pharmacy Research, 9, 3, 2025, 120-128. doi: 10.21608/aprh.2025.378030.1313
Abdul Bari, M. (2025). 'The Therapeutic Effects of Sulfasalazine Ointment on Imiquimod-Induced Psoriasis in Mice', Journal of Advanced Pharmacy Research, 9(3), pp. 120-128. doi: 10.21608/aprh.2025.378030.1313
Abdul Bari, M. The Therapeutic Effects of Sulfasalazine Ointment on Imiquimod-Induced Psoriasis in Mice. Journal of Advanced Pharmacy Research, 2025; 9(3): 120-128. doi: 10.21608/aprh.2025.378030.1313

The Therapeutic Effects of Sulfasalazine Ointment on Imiquimod-Induced Psoriasis in Mice

Article 2, Volume 9, Issue 3, July 2025, Page 120-128  XML PDF (659.71 K)
Document Type: Research Article
DOI: 10.21608/aprh.2025.378030.1313
View on SCiNiTO View on SCiNiTO
Author
Mohammed Abdul Bari email
Department of Therapeutics, Baghdad College of Medical Sciences, Baghdad, Iraq
Abstract
Objectives: Psoriasis, a chronic inflammatory skin disease affecting 0.6-4.8% of the global population, is characterized by an overproduction of pro-inflammatory cytokines and keratinocyte hyperproliferation. Current treatments often have adverse effects and high costs, necessitating new therapeutic approaches. Methods: This study investigated the potential of topical sulfasalazine, a known anti-inflammatory agent, in treating psoriasis-like inflammation using an imiquimod-induced mouse model. A 10% sulfasalazine ointment was formulated and tested against clobetasol propionate ointment and untreated controls. The efficacy was evaluated using the Psoriasis Area and Severity Index (PASI) score, histopathological examination, and measurement of pro-inflammatory cytokines (TNF-α and IL-6). Results: showed that sulfasalazine ointment significantly reduced the PASI score by 83.3%, outperforming clobetasol propionate (58.3% reduction). Histopathological analysis revealed improved skin architecture with sulfasalazine treatment, including restoration of normal dermal fibrous tissue and hair follicles. Furthermore, sulfasalazine significantly reduced levels of TNF-α (32.3% reduction) and IL-6 (19.8% reduction) compared to untreated controls. Conclusion: These findings suggest that topical sulfasalazine ointment effectively attenuates inflammation and improves clinical, histological, and molecular features of psoriasis-like lesions, potentially offering a promising alternative or complementary treatment for psoriasis management.
Keywords
Psoriasis; Sulfasalazine; Topical ointment
Main Subjects
Section D: Clinical Pharmacy & Pharmacology
Statistics
Article View: 63
PDF Download: 47
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.